MINI FUTURE LONG - ABIVAX | Real-time Bid/Ask 09:15:15 2024-05-23 am EDT | ||
| 6.86 EUR / 6.94 EUR | +0.15% |
|
| Current month | -17.78% | ||
| 1 month | -16.99% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ABIVAX
Latest news about ABIVAX
More news
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 6.97 | +1.16% |
| 24-05-22 | 6.89 | +3.45% |
| 24-05-21 | 6.66 | -4.99% |
| 24-05-20 | 7.01 | +5.73% |
| 24-05-17 | 6.63 | -0.45% |
Delayed Quote Börse Stuttgart
Last update May 23, 2024 at 04:11 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ABIVAX |
| Issuer | Morgan Stanley |
| WKN | ME3A5T |
| ISIN | DE000ME3A5T7 |
| Date issued | 2023-11-08 |
| Strike | 6.279 € |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 3.34 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.1 € |
|---|---|
| Lowest since issue | 2.91 € |
| Spread | 0.09 € |
| Spread % | 1.29% |
Company Profile
Abivax develops innovative treatments modulating the body's natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer.
As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn's disease, rheumatoid arthritis, and other inflammatory diseases (ABX464) as well as liver cancer (ABX196). The Company's mission is to utilize its drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
Sector
-
Consensus: Abivax
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
13.16
EUR
Average target price
37.46
EUR
Spread / Average Target
+184.62%
- Stock Market
- Certificates
- Certificat
